Meiogenix Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • Series B
  • (In Progress)

  • Latest Deal Amount
  • $17.6M

  • Investors
  • 10

Meiogenix General Information

Description

Developer of a biotechnology platform designed to advance crop improvement through precise, targeted recombination. The company offers proprietary breeding technologies that unlock natural genetic diversity, enabling breeders to deliver high-performing varieties that tackle challenges in productivity, sustainability, and disease resilience.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 9 Laboratory Drive
  • Suite 267
  • Durham, NC 27713
  • United States
Primary Industry
Other Agriculture
Corporate Office
  • 9 Laboratory Drive
  • Suite 267
  • Durham, NC 27713
  • United States

Meiogenix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Meiogenix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series B) 13-Oct-2025 $17.6M In Progress Generating Revenue
8. Accelerator/Incubator 25-Feb-2026 Completed Generating Revenue
7. Later Stage VC (Series A1) 05-Dec-2024 Completed Startup
6. Accelerator/Incubator Completed Generating Revenue
5. Later Stage VC (Series A) 18-Aug-2022 Completed Generating Revenue
4. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
3. Later Stage VC 20-Sep-2016 Completed Generating Revenue
2. Early Stage VC (Series A) 26-Nov-2010 $1.65M $1.65M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Meiogenix’s complete valuation and funding history, request access »

Meiogenix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Shares A
Shares P
Shares P
Shares P 6,082 $0.102096 $226.88 $226.88 $226.88 8.11%
Shares P 3,375 $0.102096 $363.01 $363.01 $363.01 4.5%
To view Meiogenix’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Meiogenix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotechnology platform designed to advance crop improvement through precise, targeted recombination. The
Other Agriculture
Durham, NC
21 As of 2026

Aptos, CA
 

New Haven, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Meiogenix Competitors (6)

One of Meiogenix’s 6 competitors is Ohalo (Other Agriculture), a Venture Capital-Backed company based in Aptos, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ohalo (Other Agriculture) Venture Capital-Backed Aptos, CA
Verinomics Venture Capital-Backed New Haven, CT
Hudson River Biotechnology Venture Capital-Backed Wageningen, Netherlands
Tropic (Horticulture) Venture Capital-Backed Norwich, United Kingdom
Cibus (Agriculture) Formerly VC-backed San Diego, CA
To view Meiogenix’s complete competitors history, request access »

Meiogenix Patents

Meiogenix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023288913-A1 Induction of meiotic recombination using a crispr system Pending 24-Jun-2022
EP-4544034-A1 Induction of meiotic recombination using a crispr system Pending 24-Jun-2022
US-20260125698-A1 Induction of meiotic recombination using a crispr system Pending 24-Jun-2022
WO-2023247773-A1 Induction of meiotic recombination using a crispr system Inactive 24-Jun-2022
AU-2021277562-A1 Use of a deficient fusion protein for nuclease activity so as to induce meiotic recombinations Pending 20-May-2020 C12N9/22
To view Meiogenix’s complete patent history, request access »

Meiogenix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Meiogenix Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Center For Entrepreneurial Development Accelerator/Incubator
Alexandria Venture Investments Venture Capital Minority
Casdin Capital Venture Capital Minority
Sofinnova Partners Venture Capital Minority
Center for Life Science Ventures Accelerator/Incubator
You’re viewing 5 of 10 investors. Get the full list »

Meiogenix FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process